UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2022

OMEGA HEALTHCARE INVESTORS, INC.

(Exact name of registrant as specified in its charter)

303 International Circle,

Suite 200

Hunt Valley, Maryland 21030

(Address of principal executive offices / Zip Code)

(410) 427-1700

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

On June 3, 2022, Omega Healthcare Investors, Inc. (“Omega””) held its Annual Meeting of Stockholders (the “Annual Meeting”).

At the Annual Meeting, the holders of 186,945,299 shares of Omega’s common stock were present in person or represented by proxy, representing approximately 78.48% of the total outstanding common stock as of the record date for the meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:

Proposal 1: Election of Directors

Proposal 2: Ratification of the selection of Ernst & Young LLP as Omega’s independent auditor for fiscal year 2022

Proposal 3: Advisory vote on Omega’s executive compensation

Each of the director nominees was elected, the selection of Ernst & Young LLP was ratified, and Omega’s executive compensation was approved on an advisory basis.

In connection with Edward Lowenthal’s retirement from Omega’s Board of Directors effective as of the completion of the Annual Meeting, Omega’s Board of Directors appointed Mr. Whitman as Chair of the Compensation Committee, to serve in this capacity until the Company’s 2023 Annual Meeting of Stockholders. As Chair of the Compensation Committee, Mr. Whitman will be compensated in accordance with the Company’s director compensation program as described in Omega’s proxy statement for the Annual Meeting.

Effective as of the completion of the Annual Meeting, the membership of the Board’s standing committees is as set forth below:

Audit Committee

Members: Kapila K. Anand (Chair), Craig R. Callen, Kevin J. Jacobs and Burke W. Whitman

Compensation Committee

Members: Barbara B. Hill, Stephen D. Plavin and Burke W. Whitman (Chair)

Investment Committee

Members: Kapila K. Anand, Craig R. Callen (Chair), Kevin J. Jacobs and C. Taylor Pickett

Nominating and Corporate Governance Committee

Members: Craig R. Callen, Dr. Lisa C. Egbuonu-Davis, Barbara B. Hill and Stephen D. Plavin (Chair)

[The balance of this page intentionally left blank]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.